Published in J Immunol on September 01, 1999
The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci U S A (2002) 2.72
Complement and periodontitis. Biochem Pharmacol (2010) 1.20
The complement system in schizophrenia. Drug News Perspect (2008) 1.02
Natural IgM mediates complement-dependent uptake of Francisella tularensis by human neutrophils via complement receptors 1 and 3 in nonimmune serum. J Immunol (2012) 1.00
Penicillin-binding protein 1a promotes resistance of group B streptococcus to antimicrobial peptides. Infect Immun (2006) 0.98
Complement genetics, deficiencies, and disease associations. Protein Cell (2012) 0.94
Critical role of the complement system in group B streptococcus-induced tumor necrosis factor alpha release. Infect Immun (2003) 0.91
Next-generation computational genetic analysis: multiple complement alleles control survival after Candida albicans infection. Infect Immun (2011) 0.87
Activation of the classical complement pathway by Bacillus anthracis is the primary mechanism for spore phagocytosis and involves the spore surface protein BclA. J Immunol (2012) 0.82
The Group B Streptococcus-Secreted Protein CIP Interacts with C4, Preventing C3b Deposition via the Lectin and Classical Complement Pathways. J Immunol (2015) 0.79
Complement inhibition by Sarcoptes scabiei protects Streptococcus pyogenes - An in vitro study to unravel the molecular mechanisms behind the poorly understood predilection of S. pyogenes to infect mite-induced skin lesions. PLoS Negl Trop Dis (2017) 0.75
Complement activation and cytokine response by BioProtein, a bacterial single cell protein. Clin Exp Immunol (2007) 0.75
Early immune responses are independent of RGC dysfunction in glaucoma with complement component C3 being protective. Proc Natl Acad Sci U S A (2017) 0.75
Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol (1982) 5.44
Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence. Proc Natl Acad Sci U S A (1987) 3.99
Identification of csrR/csrS, a genetic locus that regulates hyaluronic acid capsule synthesis in group A Streptococcus. Mol Microbiol (1998) 3.84
The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J Exp Med (1980) 3.48
Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci U S A (1983) 3.30
Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci. J Immunol (1982) 3.23
Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun (1992) 2.73
Hyaluronic acid capsule and the role of streptococcal entry into keratinocytes in invasive skin infection. J Clin Invest (1996) 2.57
Molecular analysis of the role of the group A streptococcal cysteine protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft-tissue infection. J Clin Invest (1998) 2.47
Structure and immunochemistry of an oligosaccharide repeating unit of the capsular polysaccharide of type III group B Streptococcus. A revised structure for the type III group B streptococcal polysaccharide antigen. J Biol Chem (1987) 2.35
Functional analysis in type Ia group B Streptococcus of a cluster of genes involved in extracellular polysaccharide production by diverse species of streptococci. J Biol Chem (2001) 2.30
Relative contributions of hyaluronic acid capsule and M protein to virulence in a mucoid strain of the group A Streptococcus. Infect Immun (1997) 2.13
Monocyte antigen CD14 is a phospholipid anchored membrane protein. Blood (1989) 2.10
Identification of cpsD, a gene essential for type III capsule expression in group B streptococci. Mol Microbiol (1993) 2.09
Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest (1996) 2.05
The changing spectrum of group B streptococcal disease. N Engl J Med (1993) 1.94
Hyaluronic acid capsule modulates M protein-mediated adherence and acts as a ligand for attachment of group A Streptococcus to CD44 on human keratinocytes. J Clin Invest (1998) 1.87
Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system. Blood (1985) 1.79
Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. Infect Immun (1996) 1.79
Group A Streptococcus tissue invasion by CD44-mediated cell signalling. Nature (2001) 1.76
Mature human eosinophils have the capacity to express HLA-DR. Proc Natl Acad Sci U S A (1989) 1.62
Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med (1994) 1.61
Reduction of incorrect antibiotic dosing through a structured educational order form. Arch Intern Med (1988) 1.59
Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J Exp Med (2000) 1.56
Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun (1994) 1.53
Bacterial determinants of persistent throat colonization and the associated immune response in a primate model of human group A streptococcal pharyngeal infection. Cell Microbiol (2000) 1.49
Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. J Clin Invest (1992) 1.45
Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity (1997) 1.44
Deficiency of the complement regulatory protein, "decay-accelerating factor," on membranes of granulocytes, monocytes, and platelets in paroxysmal nocturnal hemoglobinuria. N Engl J Med (1985) 1.38
Release of C8 binding protein (C8bp) from the cell membrane by phosphatidylinositol-specific phospholipase C. Blood (1988) 1.30
Structure of the has operon promoter and regulation of hyaluronic acid capsule expression in group A Streptococcus. Mol Microbiol (1998) 1.30
Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis (1999) 1.30
CD44 as a receptor for colonization of the pharynx by group A Streptococcus. J Clin Invest (2000) 1.30
Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest (1993) 1.29
Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun (1992) 1.27
Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J Immunol (1992) 1.27
Molecular analysis of the capsule gene region of group A Streptococcus: the hasAB genes are sufficient for capsule expression. J Bacteriol (1998) 1.26
Decay accelerating factor regulates complement activation on glomerular epithelial cells. J Immunol (1989) 1.24
Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9. J Immunol (1986) 1.23
Characterization of the linkage between the type III capsular polysaccharide and the bacterial cell wall of group B Streptococcus. J Biol Chem (2000) 1.21
An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus. J Biol Chem (1990) 1.18
Purification from guinea pig erythrocyte stroma of a decay-accelerating factor for the classical c3 convertase, C4b,2a. J Immunol (1981) 1.17
Phosphatidylinositol-specific phospholipase C, a possible virulence factor of Staphylococcus aureus. J Clin Microbiol (1989) 1.17
Potentiation of virulence by group B streptococcal polysaccharides. J Infect Dis (1984) 1.17
Human eosinophils express CD4 protein and bind human immunodeficiency virus 1 gp120. J Exp Med (1989) 1.16
Paramyosin inhibits complement C1. J Immunol (1992) 1.14
The presence of sialic acid on two related bacterial polysaccharides determines the site of the primary immune response and the effect of complement depletion on the response in mice. J Immunol (1982) 1.12
Regulation of capsule gene expression by group A Streptococcus during pharyngeal colonization and invasive infection. Mol Microbiol (2001) 1.10
Characterization of cpsF and its product CMP-N-acetylneuraminic acid synthetase, a group B streptococcal enzyme that can function in K1 capsular polysaccharide biosynthesis in Escherichia coli. Mol Microbiol (1996) 1.10
Cytoplasmic lipid bodies of human neutrophilic leukocytes. Am J Pathol (1989) 1.08
Immunochemical analysis of the types Ia and Ib group B streptococcal polysaccharides. J Immunol (1985) 1.07
Absence of a cysteine protease effect on bacterial virulence in two murine models of human invasive group A streptococcal infection. Infect Immun (2001) 1.06
Enhanced complement-mediated lysis of type III paroxysmal nocturnal hemoglobinuria erythrocytes involves increased C9 binding and polymerization. Proc Natl Acad Sci U S A (1985) 1.06
Group B streptococcal opacity variants. J Bacteriol (1992) 1.05
Antibody-independent activation of C1 by type Ia group B streptococci. J Infect Dis (1982) 1.04
C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion. J Immunol (1999) 1.02
Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement. J Immunol (1997) 1.02
Hormones, receptors, and cyclic AMP: their role in target cell refractoriness. Curr Top Cell Regul (1980) 1.00
Differences between agonist and antagonist binding following beta-adrenergic receptor desensitization. J Biol Chem (1978) 0.99
A transgenic mouse model for studying the clearance of blood-borne pathogens via human complement receptor 1 (CR1). Clin Exp Immunol (2005) 0.99
Combined hereditary deficiency of the sixth component of complement and factor VIII coagulant activity in a Dutch family. Clin Exp Immunol (1982) 0.99
Capsular polysaccharide regulates neutrophil complement receptor interactions with type III group B streptococci. Infect Immun (1993) 0.98
Natural killer cells are deficient in the surface expression of the complement regulatory protein, decay accelerating factor (DAF). J Immunol (1986) 0.94
Complement induces a transient increase in membrane permeability in unlysed erythrocytes. J Clin Invest (1988) 0.93
Selective alteration in high affinity agonist binding: a mechanism of beta-adrenergic receptor desensitization. Mol Pharmacol (1979) 0.90
C5L2 receptor is not involved in C3a / C3a-desArg-mediated enhancement of bone marrow hematopoietic cell migration to CXCL12. Leukemia (2005) 0.89
cDNA cloning and recombinant expression of collagen-binding and complement inhibitor activity of Taenia solium paramyosin (AgB). Mol Biochem Parasitol (1993) 0.89
Cloning, sequence analysis and expression of the group A streptococcal guaB gene encoding inosine monophosphate dehydrogenase. Gene (1995) 0.89
Molecular analysis of two group B streptococcal virulence factors. Semin Perinatol (1990) 0.89
Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine. Infect Immun (1994) 0.89
Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes. Blood (1992) 0.88
Phylogenetic analysis of the homologous proteins of the terminal complement complex supports the emergence of C6 and C7 followed by C8 and C9. J Mol Evol (1999) 0.88
Characterization of CMP-N-acetylneuraminic acid synthetase of group B streptococci. J Bacteriol (1994) 0.87
Molecular cloning and characterization of human eosinophil Charcot-Leyden crystal protein (lysophospholipase). Similarities to IgE binding proteins and the S-type animal lectin superfamily. J Immunol (1993) 0.86
Antibody CR1-2B11 recognizes a non-polymorphic epitope of human CR1 (CD35). Clin Exp Immunol (2007) 0.86
Hemolytically inactive C5b67 complex: an agonist of polymorphonuclear leukocytes. Blood (1995) 0.86
Regulation of C1q receptor expression on human polymorphonuclear leukocytes. J Immunol (1994) 0.85
Paroxysmal nocturnal hemoglobinuria. A complement-mediated disease. Complement Inflamm (1989) 0.84
The role of complement in opsonization of GBS. Antibiot Chemother (1971) (1985) 0.83
Ca2+-activated K+ efflux limits complement-mediated lysis of human erythrocytes. J Clin Invest (1989) 0.83
Characterization of the capsular polysaccharide genes of group B streptococci. Dev Biol Stand (1995) 0.83
Normal function of CR1 on affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria. J Immunol (1985) 0.83
Different functions for specific guinea pig IgG1 and IgG2 in the lysis of sheep erythrocytes by C4-deficient guinea pig serum. J Immunol (1981) 0.83
Molecular size affects antigenicity of type III, group B Streptococcus capsular polysaccharide. Trans Assoc Am Physicians (1985) 0.83
Transient changes in erythrocyte membrane permeability are induced by sublytic amounts of the complement membrane attack complex (C5b-9). Blood (1993) 0.82
Hyaluronic acid capsule modulates interactions of group A streptococci with human epidermal keratinocytes. Adv Exp Med Biol (1997) 0.80
Isolation of C4-binding protein from guinea pig plasma and demonstration of its function as a control protein of the classical complement pathway C3 convertase. J Immunol (1981) 0.79
Homologous species restriction of the complement-mediated killing of nucleated cells. Immunology (1990) 0.79
Effect of hospitalwide change in clindamycin dosing schedule on clinical outcome. Rev Infect Dis (1989) 0.79
C5a-stimulated human neutrophils use a subset of beta2 integrins to support the adhesion-dependent phase of superoxide production. J Leukoc Biol (2000) 0.79
Intercellular adhesion molecule 1 and beta2 integrins in C1q-stimulated superoxide production by human neutrophils: an example of a general regulatory mechanism governing acute inflammation. Arthritis Rheum (2000) 0.78
Serum amyloid P component forms a stable complex with human C5b6. J Immunol (1997) 0.78
Isolation of the fourth component of guinea pig complement and its single polypeptide chain precursor from plasma. Mol Immunol (1981) 0.78
Glycolipid intermediates in biosynthesis of group B streptococcal capsular polysaccharide. Adv Exp Med Biol (1997) 0.77
In vitro and in vivo responses of murine granulocytes to human complement-derived, haemolytically inactive C5b67 (iC5b67). Clin Exp Immunol (1999) 0.77
Signaling by hemolytically inactive C5b67, an agonist of polymorphonuclear leukocytes. J Immunol (1996) 0.77
Correct structure of repeating unit of group B Streptococcus type III capsular polysaccharide. J Infect Dis (1990) 0.77
Human granulocytic ehrlichiosis presenting as facial diplegia in a 42-year-old woman. Clin Infect Dis (2000) 0.76
Measurement of human antibodies to type III group B Streptococcus. Infect Immun (1999) 0.76
Into the third century of complement research. Immunol Today (2000) 0.75